Stockreport

Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024

Exact Sciences Corporation  (EXAS) 
Last exact sciences corporation earnings: 2/11 04:05 pm Check Earnings Report
PDF First analysis from ASCEND-2 confirms high detection rates and specificity achieved with multi-biomarker approach in most aggressive cancers and those with no standard-o [Read more]